Abstract: Objective To investigate the effect of oral Tongxinluo capsule on endothelial microparticles (EMPs) and matrix metalloproteinase-9 (MMP-9) level in serum of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods 144 cases of AMI patients in our hospital from August 2013 to January 2016 were randomly selected for the study and were treated with PCI. The patients were divided into the observation group and the control group by random number table. 72 patients in the control group received conventional treatment after PCI, while patients in the observation group were administered oral Tongxinluo capsule based on the conventional treatment. EMPs and MMP-9 levels of the two groups of patients before and 7 days after PCI were tested. Results EMPs and MMP-9 levels after PCI treatment of both the two groups of patients were lower than that before surgery, and the difference was statistically significant (P <0.05). EMPs and MMP-9 levels of the patients in the observation group were lower than that of the control group, and the difference was statistically significant (P <0.05). MMP-9 levels of the two groups of patients before and 7 days after PCI were both positively correlated with EMPs level (P <0.05). Conclusion Oral Tongxinluo capsule after PCI treatment for AMI patients helps to reduce EMPs and MMP-9 levels in peripheral blood, and contributes to maintain intravascular plaque stability and improve endothelial cell function.

Key words: acute myocardial infarction, percutaneous coronary intervention, Tongxinluo capsule, endothelial microparticle, matrix metalloproteinase-9